8 completed, 3 recruiting, 2 not yet recruiting. 5 Phase 4, 4 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 3, Recruiting 2 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Tadalafil 5 mg: new trials by email Literature Review of Tadalafil 5 mg trials Research Report on Tadalafil 5 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment Tadalafil 5 mg - Mild Cognitive Impairment (MCI) | Phase 2 | Not yet recruiting | Los Angeles Brain Science Project | 44 | 2026-09-01 | 2026-10-20 |
| Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy Tadalafil 5 mg, Pelvic Floor Muscle Training (PFMT), Aerobic Exercise Program - Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer | Phase 2 | Recruiting | Surgical Outcomes Research Centre (SOuRCe) | 64 | 2026-08-31 | 2026-10-23 |
| Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction Tadalafil; Current on-demand PDE5 inhibitor, Tadalafil 5 mg - Erectile Dysfunction, Tadalafil | Phase 4 | Recruiting | Al-Azhar University | 260 | 2026-08-13 | 2026-09-01 |
| Dorsal Penile Nerve Cryoneurolysis for Lifelong PE Percutaneous Dorsal Penile Nerve Cryoneurolysis, Sertraline (Oral Antidepressant), Tadalafil 5 mg - Premature Ejaculation | Not applicable | Completed | Biruni University | 117 | 2026-02-04 | 2026-10-16 |
| Combination Therapy of Tadalafil 2.5mg Plus Sildenafil 25mg Versus Tadalafil 5 mg Monotherapy for Treatment of Erectile Dysfunction: A Randomized, Placebo-Controlled Double-Blinded Cross-Over Study Tadalafil 2.5 mg, Sildenafil 25 mg, Tadalafil 5 mg - Erectile Dysfunction | Phase 3 | Not yet recruiting | Assiut University | 142 | 2025-10-01 | 2025-09-24 |
| Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study Tadalafil 5 mg, Solifenacin 5mg - Overactive Bladder (OAB), Overactive Bladder Syndrome | Phase 4 | Recruiting | Mansoura University | 480 | 2025-09-01 | 2026-02-18 |
| Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic Syndrome Tadalafil 5 mg, SGLT-2 inhibitor, Tadalafil plus SGLT2 inhibitors - Erectile Dysfunction, Left Ventricular Diastolic Dysfunction | Phase 4 | Completed | Kafrelsheikh University | 60 | 2025-05-05 | 2026-05-04 |
| Efficacy of Transcutaneous Electrical Neural Stimulation and Tadalafil in Men With Erectile Dysfunction: A Randomized, Double-Blind, Bi-centric, Placebo- and Sham-Controlled Trial Placabo, Tadalafil 5 mg, Sham stimulation - Erectile Dysfunction | Phase 4 | Completed | Menoufia University | 185 | 2025-05-01 | 2026-09-02 |
| Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study L-Arginine, Tadalafil 5 mg - Erectile Dysfunctions | Phase 4 | Completed | Fayoum University Hospital | 180 | 2024-01-14 | 2025-04-27 |
| o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer Tadalafil 5 mg - Prostate Cancer Metastatic Disease, Chemotherapy Induced Peripheral Neuropathy (CIPN) | Phase 2 | Completed | Tri-Service General Hospital (TSGH) | 90 | 2020-01-05 | 2026-01-12 |
| Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil Dutasteride 0.5 mg, Tadalafil 5 mg, YY-201 - Benign Prostatic Hyperplasia | Phase 1 | Completed | Yuyu Pharma, Inc. | 36 | 2017-03-27 | 2017-11-24 |
| A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Tadalafil 5 mg, Placebo tablet, Tamsulosin - Benign Prostatic Hyperplasia (BPH) | Phase 3 | Completed | Eli Lilly and Company | 511 | 2009-10-01 | 2012-03-12 |
| Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension Tadalafil 2.5 mg, Tadalafil 5 mg, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Completed | Eli Lilly and Company | 422 | 2008-11-01 | 2011-03-29 |
Erectile Dysfunction (6) · Prostatic Hyperplasia (3) · Cognitive Dysfunction (1) · Metabolic Syndrome (1) · Neurotoxicity Syndromes (1) · Peripheral Nervous System Diseases (1) · Premature Ejaculation (1) · Prostatic Neoplasms (1) · Urinary Bladder, Overactive (1) · Urinary Incontinence (1) · Urinary Incontinence, Urge (1) · Ventricular Dysfunction, Left (1)
Eli Lilly and Company (2) · Al-Azhar University (1) · Assiut University (1) · Biruni University (1) · Fayoum University Hospital (1) · Kafrelsheikh University (1) · Los Angeles Brain Science Project (1) · Mansoura University (1) · Menoufia University (1) · Surgical Outcomes Research Centre (SOuRCe) (1) · Tri-Service General Hospital (TSGH) (1) · Yuyu Pharma, Inc. (1)
Egypt (5) · Australia (2) · Austria (1) · Belgium (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · Poland (1) · South Korea (1) · Taiwan (1) · Turkey (Türkiye) (1)
Abul-fotouh Ahmed (1) · Ahmed A Shokeir, professor of urology (1) · Daniel Franc, MD, PhD (1) · Daniel Steffens (1) · Hyeong-Seok Lim, M.D.,Ph.D. (1) · Islam Said (1) · Mohamed Alhefnawy (1) · Mohamed G Abdelraouf, MD (1) · Reda B Bastawisy, MD (Professor) (1) · Sherif Mourad, Professor of Urology (1) · Wael A Haseeb, MD (Assistant professor) (1)